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This commentary talks about patient involvement in one of the biggest EU projects
to date—U-BIOPRED. It describes how people and carers of people with asthma
have been able to develop and drive their input and have their voice heard among
the >200 healthcare professional project members.
Five key principles for the success of the patient involvement group are presented:
involve early, involve deeply, have patients feedback on project progress, include
patients in dissemination and help patients convey their own story.
This group has been used as an example for other EU-funded projects, and the
patient involvement group will be maintained after the end of the project to ensure
that their experience and knowledge can help develop best practice in the future.
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The concept of patient and patient representative (e.g. people living with a condition,
carers, patient organisations), which will be referred to as patient throughout the paper,
involvement in healthcare and research was introduced more than 20 years ago [1, 2].
After a long journey, patient involvement in research is now being widely accepted as
important. The available evidence on its use and impact is slowly growing, primarily in
the UK [3–6], but also internationally [7, 8]. In practice, involvement is often only
‘tokenistic’—and this is particularly true for EU-funded projects (http://www.imi.euro
pa.eu/sites/default/files/uploads/documents/Publications/SurveyPatientsCalls1to6.pdf ).
In the report by the Innovative Medicines Initiative (IMI) looking at patient involve-
ment in its first six funded projects, two thirds stated that they had patient involve-
ment in their projects. However, the majority of patient involvement was in the form
of clinical trials or other forms or research where patients provided samples. Hence,
patients were used as subjects to be studied rather than having an influence on the
project itself. From direct experience, the European Lung Foundation (ELF) are often
asked to input into EU projects, usually with the request to help with dissemination of
the findings of the study to patients and the public with little involvement in the plan-
ning and delivery of the project. One of their key recommendations from the IMI© 2015 Supple et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
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sortium building, scoping) to ensure patient participation is an integrated part of the
project with adequate funding”.
Several attempts have been made to improve patient involvement in this arena, such as
VALUE+, which aimed to exchange information, experiences and good practice regarding
the meaningful involvement of patients and patient organisations in EU-supported health
projects (www.eu-patient.eu/globalassets/projects/valueplus/value-toolkit.pdf).
The 2014 European Parliament’s calendar of external events began with a workshop
organised by the European Federation of Allergy and Airways Disease Associations
(EFA; www.efanet.org) and hosted by Catherine Stihler, MEP (17 June 2014). The main
focus was to give researchers and patients the opportunity to share their visions on
how innovative EU-funded research can positively impact the lives of people with lung
conditions in Europe and how meaningful patient involvement in these projects can
become a model for the future.
During the panel discussion, Catherine Stihler highlighted the most important next
step in ensuring meaningful patient involvement—to effectively communicate the value
of meaningful patient involvement in EU projects. The panel also agreed that there is a
need for the publication of best practice papers in this arena for information and
evidence on the impact of patient involvement. This paper is a response to that action
point, and this is why it is the perfect time for Research Involvement and Engagement
to come into being to provide a journal dedicated to this kind of publication.Main text: the U-BIOPRED experience
IMI was launched under the EU Framework 7 programme as a public-private partnership
focused on bottlenecks in drug discovery. IMI clearly identified patients as important
stakeholders. U-BIOPRED (Unbiased Biomarkers in Prediction of Respiratory Disease
Outcomes) is an IMI-funded EU research project using information and samples from
adults and children to learn more about different types of asthma to ensure better diagno-
sis and treatment for each person [9]. The project had a total funding of €26,925,702. Of
this, €488,900 was for patient organisation and patient involvement in the project (2 %).
The U-BIOPRED project was one of the first IMI projects. A Patient Input Platform
(PIP) was established at the start of U-BIOPRED to work together to provide the
patients’ perspective, support and insight into the project’s different research and dis-
semination processes, with a view to helping the research stay ‘connected’ to the patient
experience and needs. During the submission phase of the grant, two national (the
Lung Foundation (Netherlands) and Asthma UK (UK)) and one European patient
organisation (EFA), as well as the ELF and its patient organisation network, were asked
to provide input into the initial proposals. Patients from these groups then went on to
being part of the project. Patients were also included in the project’s multidisciplinary
ethics and safety monitoring boards as well as the project’s strategic advisory board.
Patients took part on the U-BIOPRED boards on a completely voluntary basis using
their personal titles. Travel and lodgings were covered for each meeting, but no pay-
ment was made to the individuals for the time taken out of work and home life. The
patients involved in the project were supported by their individual organisation’s secre-
tariat for the duration of the project and centrally by a coordinator and responsible
Supple et al. Research Involvement and Engagement  (2015) 1:5 Page 3 of 9individual in the project who was recompensed for involvement through the patient
organisation for which he worked.
From the outset, U-BIOPRED included patient organisations, and the PIP, not just as
advisers but also as participating partners in the project. Accordingly, U-BIOPRED has
strived to increase patient involvement in research beyond tokenism. The objectives of
U-BIOPRED are ambitious. Some said too ambitious at the outset. However, now more
than 4 years into the project, it is clear that U-BIOPRED will deliver on all of its objec-
tives. This is in no small part due to the dedication and hard work of all project part-
ners and the commitment to work in a highly integrated manner, more like a virtual
network than a loose collection of separate centres of excellence. Patients are very
much a part of this U-BIOPRED virtual network and have, in fact, aided its cohesion as
they transcend work package boundaries and give a much-needed overview of the pro-
ject as a whole.
As the meaningful involvement of patients has spread throughout U-BIOPRED, a
number of best practices have emerged. These best practices are outlined below with
examples of how they were implemented and their impact on the project as a whole.
Involve early
Patient input is often most impactful in the project formation phase [10–14]. Re-
searchers tend to have a focus on scientific questions and less on the wider context of
disease. Patients can bring the perspective of what it is like to live with a disease, or
several diseases/comorbidities and the balancing act that is required to manage them.
Early patient input ranges from practical aspects, such as how to prepare documents to
be understood by people without a background in science and how much a study par-
ticipant should be asked to do per study visit, to more strategic input, such as how to
recruit study participants from a representative breadth of socioeconomic backgrounds.
In practice
By having patient organisations, and their patients, as funded partners, a patient
perspective was incorporated into even the earliest drafts of the project proposal
and work plan. These organisations (Asthma UK and Lung Foundation) invited
their patient members to join the PIP, and get involved by, for example, reviewing
the informed consent forms and study protocol. As a result, changes were made to
both the consent forms, practical parts of the protocols directly affecting study par-
ticipants, and the structure of the study visits. For the consent forms, the main
issues highlighted by the PIP were as follows: there were too many forms in differ-
ent formats and hence they were harmonised and reduced in number, to ensure
that the forms were available in all appropriate languages and the issue of support
for completing the questions was highlighted so this could be provided on site at
clinical centres. For the study visits, they were reduced in number to one and
therefore more procedures were carried out in one visit. This was due to the
patient perspective that taking time out of work to go to hospital was difficult, and
if you were going to attend, it would be better to do in one go. The paediatric
study visits were modified to better accommodate the reality of a parent having to
bring the child to a study visit and the child being able to tolerate the length of
the visit. The visits were therefore, in this instance, made shorter. In addition,
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missing from the information sheet and added after the PIP advice.Impact
A more participant-friendly study design and consent form helped with recruitment
and participant withdrawal. The lack of studies on paediatric patients is one of the
frequently highlighted gaps in translational research [15]. U-BIOPRED has delivered a
paediatric cohort of 299 participants: 102 severe asthma school age, 58 severe asthma
pre-school, 83 mild/moderate asthma school age and 56 mild/moderate asthma pre-
school participants. Early patient involvement in study design helped to make this pos-
sible. Often lacking from clinical studies, study participants were also informed about
the study progress during the study subsequent to the intervention of the PIP and com-
munication action by the patient organisations, such as adding a newsletter sign-up
page to the website, sending twice yearly project updates to the participants, creating a
Twitter page and LinkedIn group.Involve deeply
In order to have meaningful input, patient involvement needs to be more than a patient
meeting at the beginning and the end of a project [16]. There is a perception that
patients either will not understand or would not be interested in the day-to-day opera-
tions of a research project. This often means that patients are given simplified and
inaccurate explanations of how a project is progressing, what the challenges are and
what the results mean. In reality, the more patients are involved in the day-to-day activ-
ities of the project, and the more they are informed about its progress, the more they
can understand, contribute and positively impact.In practice
In U-BIOPRED, PIP members take part in the research working groups, not only the
annual meetings but also the monthly or even weekly operational conference calls. One
of the studies in U-BIOPRED will establish a research methodology for giving the
common cold virus to people with asthma to make their asthma worse so that
researchers can test the effectiveness of new therapies to treat the common cold in
people with asthma. If we wait for someone to get worse, it is difficult to involve
them in a coordinated study, plus getting a cold in real life is much more serious
than the mild worsening provoked by the virus dose given in the study. Patient
representatives regularly attend the operation calls for this study and have a deep
understanding of the issues being faced, making them able to participate in the
decision-making. Decisions made with patient input have included limiting the
number of questionnaires, deciding to include more centres to achieve recruitment
goals, decision to not have trials using animals and the need to develop informa-
tion sheets on rhinovirus and bronchoscopy (final products produced with the
patients telling their experiences can be found here: http://www.europeanlung.org/
en/projects-and-research/projects/u-biopred/news-and-events/news/what-is-a-bronch
oscopy-and-why-is-it-important-in-u-biopred).
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Patient perception incorporated into decision-making and issue resolution means more
efficiency. Instead of finding out months into the study that study participants were
withdrawing from the study because of too many questionnaires, the protocol was
modified in a proactive fashion thanks to patient input. The production of factsheets
that answered study participants’ questions about certain aspects of the trials and pro-
cedures also helped recruitment.Have patients feedback of project progress
There are no better taskmasters than those who have the biggest stake in the success of
a project—the people who the outcomes of the study will impact the most in the long
run.In practice
In the initial stages of U-BIOPRED, it was motivating to hear the patient representa-
tives who attended the annual meeting saying that they wanted the project to “just get
on with it” instead of all the intense discussions that were taking place around the pro-
ject setup and resulting issues. This was also a reflection of the learning process for the
patient representatives. The amount of effort and complexities in setting up an ambi-
tious project like U-BIOPRED was a surprise to them. The patients gained real insight
and experience through being party to this process. This has given them the knowledge
and experience to get involved in other EU projects.Impact
At a point when positivity was low within the project because of the difficulties being
faced, it was helpful to have the patient voice urging the project forward, motivating
the project members to work together. As project coordinator Prof. Peter Sterk stated
during the 2013 U-BIOPRED annual general meeting in Barcelona—“The voice of the
PIP here today encouraging us to move forward to fulfil our project goals is what we
need to hear to push us forward with even more commitment and vigor in the coming
year”. It forced the project partners to reflect on why they were doing this study, i.e. for
the patients’ health.Include patients in dissemination
Patient advocates are very good at spreading the word about their disease and advances
being made. They often have a more prominent presence on social media than clini-
cians and researchers, are committed to using it as a medium and can be relied upon
to post regularly.In practice
In U-BIOPRED, patients and patient organisations were utilised to disseminate import-
ant outcomes in U-BIOPRED. It is all too easy to focus solely on scientific publications.
Yet, the general public is where the support for research comes from.
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Patients can provide a highly valuable insight as reviewers of dissemination resources,
such as checking messages for relevance and tone for the general public, and pushing
for lay summaries of all publications coming out of the project. For publications com-
ing out of U-BIOPRED, telephone calls were held with paper authors and members of
the PIP. Members of PIP provided feedback to the authors about their papers,
highlighted parts that they felt needed more emphasis from the patient perspective. In
addition, together with the authors, the PIP helped to draft the lay summaries for each
paper. PIP members have also been speakers in mainstream symposia and educational
workshops at the European Respiratory Society (ERS) International Congress to speak
about the project from their viewpoint.
The patients involved in the U-BIOPRED project also provided a core of social media
connections that can help messages spread more widely. U-BIOPRED as a project has 170
followers on Twitter; however, regular tweets from the U-BIOPRED PIP members have a
much greater reach, for example, Amanda Robert’s, Val Hudson’s and David Supple’s
tweets on the project reach upwards of 4,999, 3,244 and 690 followers, respectively.
Patients convey their own story
The story of a patient provides powerful inspiration.
In practice
U-BIOPRED held an ‘Asthma Art’ contest. People with asthma were asked to submit a
piece of art that depicted how they felt about their asthma. The researchers and staff in
U-BIOPRED then judged the submitted art. A total of 100 researchers selected 1 entry
out of 12. An 18-year-old person with asthma was chosen as the winner. Her dark and
claustrophobic-feeling image skillfully represents what is it like to have asthma. Patients
have also contributed their experiences for information sheets on having a bronchoscopy
and taking part in the cold study to support recruitment and engagement.
Impact
Judging those pieces of art gave the U-BIOPRED researchers the motivation to persist in
moving forward despite what, at times, seemed to be insurmountable challenges. The
winner of the contest has gone on to become an active patient advocate, representing her-
self and others with asthma. It is important and useful to remind researchers why they are
doing what they are doing. There is no more powerful way to do this than when patients
tell their story. In addition, on the U-BIOPRED website, there is an opportunity for people
living with asthma to share their stories, and this section has been viewed 159 times and
remains one of the most popular pages on the project website (http://www.europeanlun
g.org/en/projects-and-research/projects/u-biopred/news-and-events/art-contest-2011).
Barriers and difficulties
Although there is a positive message about the future of patient involvement in EU-
funded projects, the barriers should be noted so that action can be taken to overcome
these, including:
 Language and adequate representation
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that they can understand all communications coming from the project and follow
meetings. Novel ways need to be found to ensure that a wider group of patients can
participate—these include multilingual surveys, focus groups being held in individual
countries and resources and news being regularly translated.
 Travel capacity
Travelling to face-to-face meetings across Europe can be difficult and time-
consuming, especially for patients who are not in the best health. Issues can also
arise from costs of travel insurance, etc. Where possible, involvement should be
facilitated by phone and internet to ensure all those willing to participate can.
The value of face-to-face meetings is still high however. And EU projects
should ensure that they cover all costs that patients incur if they are able to
travel to join meetings, with minimal pre-payment being required by the patient.
 Time of work or being able to get away from the home situation
If meeting are held across Europe, there is often two or more days required
to travel and take part. If these days are not recompensed, as was the case in
U-BIOPRED, then it is often difficult for people with work or home commitments
to take that time out. EU projects should look to following the example of
organisations such as the European Medicines Agency (EMA) and consider
paying a day rate.
 Duration of commitment
The U-BIOPRED project has run for 6 years in total, and this has been a long time
to commit to the project. The majority of original patients are still involved, although
at some points, some have played a more active role than others. It is important to
ensure that the roles people can play can be amended to fit their health situation at
any time and are flexible enough to encourage commitment at whatever level is
possible and of interest to them.
 Lack of knowledge on specific topics
Sometimes, it is difficult for patients to follow the discussions and activities in EU
projects due to a lack of understanding about topics such as clinical trials,
procedures required to run clinical trials, terminology used to described different
techniques, etc. There are many programmes and activities that have been
established to try and address this issue. Two examples are EPAP (the European
Ambassador Patient Ambassador Programme —www.EPAPonline.eu), which
aims to provide patients with any chronic disease and carers with the essential
skills and knowledge needed to interact with healthcare professionals, policymakers,
researchers and journalists, and EUPATI (European Patients Academy on
Therapeutic Innovation—http://www.patientsacademy.eu/index.php/en/), a more
in-depth course on research, which provides scientifically reliable, objective,
comprehensive information to patients on medicines research and development.
 Effective collaboration
In order for patient involvement to be truly productive, the healthcare professionals
and scientists involved in the project needs to embrace and accept the patient
perspective—their views and opinions. There is no doubt that attitudes have
changed dramatically even over the course of the U-BIOPRED project—with
those skeptical about the impact of patient involvement at the beginning of
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as this and published evidence of the impact of patient involvement is,
however, still vitally needed to ensure that impact of patient involvement is
fully understood and appreciated. ELF worked with the ERS recently to hold
an online course for professionals outlining the advantages for them of public
involvement (http://www.ers-education.org/events/courses/from-research-to-
bedside-the-benefits-of-involving-patients-in-respiratory-healthcare.aspx). This
kind of education and further training to students and scientists is vital if
patient involvement in EU projects is going to continue to grow.Conclusions
The journey for patients working in EU projects has only just started, and the future is
exciting. The more patients get involved, the more opportunities for impact can be
realised.
The U-BIOPRED PIP does not stop here either. The expertise from the group will
not be lost, as EFA, together with the ELF (www.europeanlung.org), is facilitating the
further development and expansion of PIP as an independent group of patient advo-
cates from across Europe who can contribute their knowledge and experience of EU
research to ensure meaningful patient engagement in future EU-funded research. There
are plans to evolve this group to allow it to provide advice to others and to act on a
consultancy basis for other patient groups in other projects and other disease areas.
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